Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations.

Acquisition includes INZ-701, a late-stage enzyme replacement therapy targeting ectonucleotide ...

PE: How can digital solutions address gaps in women’s healthcare? Partridge: Digital solutions play a crucial role in ...

Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why seamless communication and treatment continuity across ...

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

Polanco, executive VP and chief commercial officer, Novartis US, and the 2025 Healthcare Businesswomen’s Association Woman of ...

Zynyz is the first and only FDA-approved first-line treatment for adult patients with inoperable locally recurrent or ...

Weight-loss and diabetes drugs dominated pharmaceutical spending last year, according to a new report by the American Society ...

Our exclusive poll captures today's top trends and perspectives—shaped by those pharma decision-makers impacted the most.

The order pushes drug companies to reduce drug prices in the United States to fall in line with other countries around the ...

Welireg marks the first FDA-approved non-surgical treatment option for locally advanced, unresectable, or metastatic ...

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...